Abstract
It is well known that calorie restriction (CR) can retard the aging process in organisms ranging from yeast to non-human primates, and delay the onset of numerous age-related diseases including neurodegenerative disorders. Translation of the knowledge gained from CR research in animal models to disease prevention strategies in humans should provide therapeutic approaches for these diseases. Signaling pathways induced by CR are therefore potentially new therapeutic targets for neurodegenerative diseases. This review summarizes the evidence on key biological mechanisms underlying the beneficial effects of CR based on our current understanding, with particular emphasis on the recent impact of CR on neuroprotection, and on the emerging development of pharmacological agents that target signaling pathways induced by CR. We focus in particular on recent findings on sirtuins for prevention of neurodegenerative diseases.
Keywords: Calorie restriction, neurodegeneration, sirtuins, neurotrophin, PPAR, chaperone proteins, autophagy, Yeast, Non-human primates, Signaling pathways, Neuroprotection, Calorie restruction, PPARs, Biomarkers, Meal frequency, Glucose tolerance, Triiodothyronine, Alzheimer's disease, Parkinson's disease, Stroke, Substantia nigra, Cerebral occlusion, Huntington's disease, Amyotrophic lateral sclerosis, Calorie intake, Aging, C. elegans, Drosophila, Wallerian degeneration, p53, FOXO, PGC-1α, HSF1, Ku70, Calorie mimetics, NGF, BDNF, GDNF, Mitochondria, Antioxidant, Reservatrol, Multiple sclerosis, Rapamycin, CR mimetics
Current Drug Targets
Title: Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Volume: 11 Issue: 10
Author(s): Wenzhen Duan and Christopher A. Ross
Affiliation:
Keywords: Calorie restriction, neurodegeneration, sirtuins, neurotrophin, PPAR, chaperone proteins, autophagy, Yeast, Non-human primates, Signaling pathways, Neuroprotection, Calorie restruction, PPARs, Biomarkers, Meal frequency, Glucose tolerance, Triiodothyronine, Alzheimer's disease, Parkinson's disease, Stroke, Substantia nigra, Cerebral occlusion, Huntington's disease, Amyotrophic lateral sclerosis, Calorie intake, Aging, C. elegans, Drosophila, Wallerian degeneration, p53, FOXO, PGC-1α, HSF1, Ku70, Calorie mimetics, NGF, BDNF, GDNF, Mitochondria, Antioxidant, Reservatrol, Multiple sclerosis, Rapamycin, CR mimetics
Abstract: It is well known that calorie restriction (CR) can retard the aging process in organisms ranging from yeast to non-human primates, and delay the onset of numerous age-related diseases including neurodegenerative disorders. Translation of the knowledge gained from CR research in animal models to disease prevention strategies in humans should provide therapeutic approaches for these diseases. Signaling pathways induced by CR are therefore potentially new therapeutic targets for neurodegenerative diseases. This review summarizes the evidence on key biological mechanisms underlying the beneficial effects of CR based on our current understanding, with particular emphasis on the recent impact of CR on neuroprotection, and on the emerging development of pharmacological agents that target signaling pathways induced by CR. We focus in particular on recent findings on sirtuins for prevention of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Duan Wenzhen and A. Ross Christopher, Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011281
DOI https://dx.doi.org/10.2174/1389450111007011281 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
Current Drug Targets Functional Annotation of Genes Overlapping Copy Number Variants in Autistic Patients: Focus on Axon Pathfinding
Current Genomics Drug Target Identification for Neuronal Apoptosis Through a Genome Scale Screening
Current Medicinal Chemistry Neuroprotective Role of Nutritional Supplementation in Athletes
Current Molecular Pharmacology Curcumin, an Active Constiuent of the Ancient Medicinal Herb Curcuma longa L.: Some Uses and the Establishment and Biological Basis of Medical Efficacy
CNS & Neurological Disorders - Drug Targets Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Linkage of Stress with Neuromuscular Disorders
CNS & Neurological Disorders - Drug Targets Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP Mice
Letters in Drug Design & Discovery Enhanced Tolerance against Early and Late Apoptotic Oxidative Stress in Mammalian Neurons through Nicotinamidase and Sirtuin Mediated Pathways
Current Neurovascular Research Physical Exercise for the Treatment of Neuropsychiatric Disturbances in Alzheimer’s Dementia: Possible Mechanisms, Current Evidence and Future Directions
Current Alzheimer Research Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy
Current Neuropharmacology Clinical Applications of Mesenchymal Stem Cells in Laryngotracheal Reconstruction
Current Stem Cell Research & Therapy Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Antisense Technology: A Selective Tool for Gene Expression Regulation and Gene Targeting
Current Pharmaceutical Biotechnology Phytochemicals as Substances that Affect Astrogliosis and their Implications for the Management of Neurodegenerative Diseases
Current Medicinal Chemistry The Protective Effects of Jatrorrhizine on β-Amyloid (25-35)-Induced Neurotoxicity in Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Amendatory Effect of Flavonoids in Alzheimer's Disease Against Mitochondrial Dysfunction
Current Drug Targets Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research